Jefferies reduced its rating on Halozyme Therapeutics HALO from Hold to Underperform and cut its price target from $8 to $3 following an FDA hold on clinical trials of an important growth driver to the company.
Jefferies said, "As expected HyQ gets CRL, but more importantly, FDA puts a clinical hold on rHuPH20 trials for HyQ & Cinryze. Given HALO's value is entirely based on its rHuPH20 platform, this raises significant uncertainty on its future (unlikely additional partnership opportunity, conceivable termination of BAX/VPHM deals). Even if Roche's SC Herceptin/SC MabThera get thru U approval, commercial potential is small from our previous survey data."
Halozyme Therapeutics closed at $8.56 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in